The Effect of MK 0633 in Patients With Atherosclerosis (0633-008)(COMPLETED)

Merck Sharp & Dohme (MSD) logo

Merck Sharp & Dohme (MSD)

Status and phase

Completed
Phase 2

Conditions

Atherosclerosis

Treatments

Drug: MK0633

Study type

Interventional

Funder types

Industry

Identifiers

NCT00421278
MK0633-008
2006_563
0633-008

Details and patient eligibility

About

A study to test the effects of study drug (MK 0633) on patients with Atherosclerotic disease

Enrollment

180 patients

Sex

Male

Ages

40 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with plaque in coronary or leg arteries, known as atherosclerosis or peripheral vascular disease
  • Inflammatory marker found in your blood, known as hsCRP > 0.5 mg/L

Exclusion criteria

  • Age < 40 or > 85
  • Female
  • Heart attack, coronary artery bypass, stroke or unstable angina in last 3 months
  • Liver diseased or abnormalities
  • HIV infection
  • Lupus, rheumatoid arthritis, cancer <5 years

Trial design

180 participants in 1 patient group

1
Experimental group
Description:
Arm 1: Drug
Treatment:
Drug: MK0633

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems